NO981633L - Farmas÷ytisk blanding for administrering av en aktiv forbindelse til eller gjennom hud eller en mukosaoverflate - Google Patents

Farmas÷ytisk blanding for administrering av en aktiv forbindelse til eller gjennom hud eller en mukosaoverflate

Info

Publication number
NO981633L
NO981633L NO981633A NO981633A NO981633L NO 981633 L NO981633 L NO 981633L NO 981633 A NO981633 A NO 981633A NO 981633 A NO981633 A NO 981633A NO 981633 L NO981633 L NO 981633L
Authority
NO
Norway
Prior art keywords
analogs
composition
active substance
prodrugs
solubility
Prior art date
Application number
NO981633A
Other languages
English (en)
Other versions
NO981633D0 (no
Inventor
Lise Sylvest Nielsen
Jens Hansen
Original Assignee
Gs Dev Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gs Dev Ab filed Critical Gs Dev Ab
Publication of NO981633D0 publication Critical patent/NO981633D0/no
Publication of NO981633L publication Critical patent/NO981633L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Farmasøytiske sammensetninger for administrering av en aktiv substans til eller gjennom en skadet eller uskadet hud eller mukosaoverflate eller til det orale hulrommet inkludert tennene til et dyr slikt som et menneske. Blandingen har fordelaktige egenskaper med hensyn på frigjøring av den aktive substansen fra blandingen og, videre, er blandingen bioadhesiv. Blandingen innbefatter den aktive substansen og en effektiv mengde av en fettsyreester som, sammen med en flytende fase, kan generere en flytende krystallinsk fase der bestanddelene av blandingen er innesluttet, der den aktive substansen har en løselighet i den flytende krystallinske fasen på det meste 20 mg/g ved 20 °C, og en løselighet i vann på det meste 10 mg/ml ved 20 °C, vannet, der det er passende, er bufret til en pH som er vesentlig lik den pH som er rådende i den flytende krystallinske fasen (pH ca. 3,6-9). Blandingen er spesielt egnet for administrering av substanser som har en veldig lav vannløselighet og som skal bli gitt i en effektiv mengde til en lokalisert region over en tidsperiode. Aktive substanser med spesiell viktighet er anti-herpesvirusagenser inkludert antivirale legemidler og prodroger derav, slik som nukleosider, nukleosid- analoger, fosforylerte nukleosider (nukleotider), nukleotidanaloger og salter, komplekser og prodroger derav; f.eks. guanosinanaloger, deoksyguanosinanaloger, guanin, guaninanaloger, tymidinanaloger, uracilanaloger og adeninanaloger. Spesielt interessante anti-herpesvirusagenser til bruk enten alene eller i kombinasjon i en blanding i henhold til den foreliggende oppfinnelsen er valgt fra acyklovir, famciklovir, deciklovir, penciklovir, zidovudin, ganciklovir, didanosin, zalcitabin, valaciklovir, sorivudin, lobukavir, brivudin, cidofovir, n-dokosanol, ISIS-2922, og prodroger og analoger derav.
NO981633A 1995-10-12 1998-04-08 Farmas÷ytisk blanding for administrering av en aktiv forbindelse til eller gjennom hud eller en mukosaoverflate NO981633L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK115095 1995-10-12
PCT/DK1996/000437 WO1997013528A1 (en) 1995-10-12 1996-10-11 A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface

Publications (2)

Publication Number Publication Date
NO981633D0 NO981633D0 (no) 1998-04-08
NO981633L true NO981633L (no) 1998-06-04

Family

ID=8101575

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981633A NO981633L (no) 1995-10-12 1998-04-08 Farmas÷ytisk blanding for administrering av en aktiv forbindelse til eller gjennom hud eller en mukosaoverflate

Country Status (7)

Country Link
EP (1) EP0871489A1 (no)
JP (1) JPH11513393A (no)
AU (1) AU702030B2 (no)
CA (1) CA2231273A1 (no)
FI (1) FI980822A0 (no)
NO (1) NO981633L (no)
WO (1) WO1997013528A1 (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440980B1 (en) 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
AU6919598A (en) * 1997-04-17 1998-11-13 Dumex-Alpharma A/S A novel bioadhesive drug delivery system based on liquid crystals
CA2294988C (en) 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
WO1999007341A1 (en) * 1997-08-09 1999-02-18 Smithkline Beecham Plc Compositions for nasal administration
PT942780E (pt) * 1997-09-09 2003-11-28 Lyotropic Therapeutics Inc Particulas revestidas processos de obtencao e uso
SE9703458D0 (sv) * 1997-09-25 1997-09-25 Pharmacia & Upjohn Ab Nicotine compositions and methods of formulation thereof
WO1999060012A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
US7030155B2 (en) 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9827034D0 (en) * 1998-12-10 1999-02-03 Univ Manchester Delivery formulation
US7556827B1 (en) * 1999-08-06 2009-07-07 Max-Delbrück-Centrum-für Molekulare Medizin Implantable active ingredient depot
AU2012101A (en) * 1999-12-20 2001-07-03 New Pharma Research Sweden Ab Veterinary compositions
DE10057769A1 (de) 2000-11-22 2002-05-23 Beiersdorf Ag Haarpflegeprodukte mit einem Gehalt an dispersen Flüssigkristallen, welche kubische Phasen darstellen
PT1390378E (pt) * 2001-04-30 2009-07-23 Trommsdorff Arzneimittel Ésteres de uridina farmaceuticamente activos
US7439271B2 (en) * 2001-06-27 2008-10-21 The Gillette Company Reduction of hair growth
US20030124196A1 (en) 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
JP2007504256A (ja) * 2003-09-01 2007-03-01 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド 生物活性剤の送達のための組成物及び方法
WO2006075124A1 (en) * 2005-01-14 2006-07-20 Camurus Ab Somatostatin analogue formulations
US8236292B2 (en) * 2004-06-04 2012-08-07 Camurus Ab Liquid depot formulations
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9592324B2 (en) 2006-11-06 2017-03-14 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
EP1811935B1 (en) 2004-09-28 2016-03-30 Atrium Medical Corporation Heat cured gel and method of making
US20060067977A1 (en) 2004-09-28 2006-03-30 Atrium Medical Corporation Pre-dried drug delivery coating for use with a stent
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9757461B2 (en) 2005-01-14 2017-09-12 Camurus Ab GnRH analogue formulations
PL1848403T3 (pl) * 2005-01-14 2010-09-30 Camurus Ab Preparaty bioadhezyjne o działaniu miejscowym
EP1843746B1 (en) 2005-01-14 2011-03-16 Camurus Ab Somatostatin analogue formulations
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
KR101245022B1 (ko) 2005-01-21 2013-03-19 카무러스 에이비 약제학적 지질 조성물
CN101170997A (zh) * 2005-05-10 2008-04-30 诺瓦提斯公司 改进释放的泛昔洛韦药物组合物
EP1888031B1 (en) 2005-06-06 2013-01-23 Camurus Ab Glp-1 analogue formulations
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
AU2006304590A1 (en) 2005-10-15 2007-04-26 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
DK2086504T3 (da) 2006-10-17 2014-04-07 Nuvo Res Inc Diclofenac-gel
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
EP2288898B1 (de) * 2008-06-09 2015-08-12 Boehringer Ingelheim International GmbH Vorrichtung und verfahren zur ermittlung der eigenschaften von aerosolformulierungen
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
US8546450B1 (en) 2009-03-31 2013-10-01 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
EP2498754B1 (en) * 2009-06-25 2018-06-06 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Reverse hexagonal mesophases (h ii) and uses thereof
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US10322213B2 (en) 2010-07-16 2019-06-18 Atrium Medical Corporation Compositions and methods for altering the rate of hydrolysis of cured oil-based materials
BR112014029425A2 (pt) 2012-05-25 2017-06-27 Camurus Ab pré-formulação, dispositivo de administração pré-cheio, kit, processo para a formação de uma pré-formulação, usos de mistura e de um solvente polar, e, método para o tratamento de um sujeito
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
WO2014016428A1 (en) 2012-07-26 2014-01-30 Camurus Ab Opioid formulations
HRP20210068T1 (hr) 2012-07-26 2021-03-05 Camurus Ab Opioidne formulacije
AU2018255718A1 (en) 2017-04-20 2019-12-05 Zeenar Enterprises Pty Ltd Fast disintegrating tablet
WO2018191794A1 (en) 2017-04-20 2018-10-25 Zeenar Enterprises Pty Ltd Liquid crystalline dosage form for administering a statin
WO2020050423A1 (ja) * 2018-09-07 2020-03-12 株式会社ファルネックス 非ラメラ液晶形成脂質を含む外用剤
AU2019368537B2 (en) * 2018-10-25 2025-05-08 Cubopharm Pty Ltd Composition that forms liquid crystalline particles
CN111821254B (zh) * 2019-04-18 2021-10-15 华东师范大学 一种抗病毒水凝胶及其制备方法和应用
CN111759858B (zh) * 2020-06-02 2022-09-20 杭州英健生物科技有限公司 pH敏感型消化道粘膜保护胶及其应用
CN112791047A (zh) * 2021-01-15 2021-05-14 中国人民解放军总医院第三医学中心 一种白藜芦醇层状液晶及其制备方法
CA3235606A1 (en) * 2021-10-19 2023-04-27 Sensach Ab Lipid patch
WO2023189270A1 (ja) * 2022-03-28 2023-10-05 富士フイルム株式会社 生体用組成物
JPWO2023189273A1 (no) * 2022-03-28 2023-10-05
AU2023354243A1 (en) * 2022-09-26 2025-04-03 Universität Bern Structured lipid compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2631282A1 (de) * 1976-07-12 1978-01-19 Kali Chemie Pharma Gmbh Verfahren zur erhoehung der loeslichkeit und des dispersitaetsgrades von schwerloeslichen arzneistoffen zum zwecke deren applikation in gelatinekapseln
SE457933B (sv) * 1987-07-06 1989-02-13 Larsson Kare Farmaceutisk komposition innefattande en vattendispergerad blandning av lipider, monoglycerider och fosfatidylkolin samt dess anvaendning foer framstaellning av en gastronintestinalt verksam kompostion
ES2119748T3 (es) * 1990-03-23 1998-10-16 Yoshitomi Pharmaceutical Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
ATE180971T1 (de) * 1994-03-30 1999-06-15 Gs Dev Ab Verwendung von fettsäureester als bioklebstoffe

Also Published As

Publication number Publication date
WO1997013528A1 (en) 1997-04-17
JPH11513393A (ja) 1999-11-16
AU7279296A (en) 1997-04-30
CA2231273A1 (en) 1997-04-17
EP0871489A1 (en) 1998-10-21
FI980822A7 (fi) 1998-04-09
AU702030B2 (en) 1999-02-11
FI980822A0 (fi) 1998-04-09
NO981633D0 (no) 1998-04-08

Similar Documents

Publication Publication Date Title
NO981633L (no) Farmas÷ytisk blanding for administrering av en aktiv forbindelse til eller gjennom hud eller en mukosaoverflate
HUP0302334A2 (hu) Vírusellenes hatású nukleozid-vegyületek prekurzorjai, valamint e vegyületek alkalmazása gyógyászati készítmények előállítására
de Clercq Milestones in the discovery of antiviral agents: nucleosides and nucleotides
KR900015742A (ko) 항 비루스 제
EA005774B1 (ru) 3'-ПРОЛЕКАРСТВА 2'-ДЕЗОКСИ-β-L-НУКЛЕОЗИДОВ
RU2006147216A (ru) Бета-l-2` дезокси-нуклеозиды для лечения гепатита в
TNSN99183A1 (fr) Compose chimique
BR0008498A (pt) Método de promoção de hidratação de mucosas com certos difosfatos de uridina, adenina e citidina e seus análogos
HU198394B (en) Process for production of synergetic antiviral medical composition
WO2006113204A2 (en) Thymidine derivatives for treatmemt of kaposi's sarcoma
US6358963B1 (en) Antiviral nucleoside analogues
SI9820003A (sl) Zdravljenje bolezni povezano s citokini
US12454540B2 (en) Prodrugs of L-BHDU and methods of treating viral infections
EP2968228A1 (en) Combined systemic and topical treatment of disordered tissues
Gangadhara et al. Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents
EP1778254A2 (en) Prodrugs activated by rna-dependent dna-polymerases
US4044122A (en) Method of treating herpes virus hominis infections
EA051236B1 (ru) Пролекарства l-bhdu и способы лечения вирусных инфекций
HK40108241A (zh) L-bhdu的前药和治疗病毒感染的方法
RU98100411A (ru) Производные ацикловира для локального применения
US20100137341A1 (en) Dna polymerase inhibitors composition and methods
US20090004101A1 (en) Method and Means for Enhanced Pulmonary Drug Delivery
ECSP993155A (es) Compuestos quimicos
WO1993000099A2 (de) Verwendung von pyrimidin- und purinnucleosiden zur prophylaxe und/oder behandlung von durch adenoviren verursachten infektionen
Sanghvi Synthesis of 5′-O-Amino-2′-deoxypyrimidine and Purine Nucleosides: Building-Blocks for Antisense Oligonucleosides

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application